EGFR exon 19 deletion in advanced NSCLC: osimertinib 1L improves OS vs first-generation E...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-EGFR-EX19DEL-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-EGFR-MUTATION |
|---|---|
| Variant | exon 19 deletion |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | osimertinib monotherapy, osimertinib + pemetrexed/platinum (FLAURA2 regimen), amivantamab + lazertinib (MARIPOSA, 1L alternative) |
| Evidence summary | EGFR exon 19 deletion in advanced NSCLC: osimertinib 1L improves OS vs first-generation EGFR-TKIs (FLAURA, Soria et al. 2018; Ramalingam 2020). Adjuvant osimertinib post-resection improves DFS (ADAURA, Wu et al. 2020). Exon 19 del is one of two classical sensitizing mutations (with L858R) and predicts the highest TKI response rates. |
Notes
ESCAT IA. OncoKB Level 1. Companion diagnostic: cobas EGFR Mutation Test v2, FoundationOne CDx. Universal testing required for advanced non-squamous NSCLC.
Used By
No reverse references found in the YAML corpus.